




# La recherche en santé : nouveaux modèles, nouveaux leviers

Ruxandra Draghia-Akli, MD, PhD  
Directrice Santé  
DG Recherche et Innovation

HORIZON 2020

Rencontres du G5 santé; Paris, 18 Novembre 2014



## Health, Demographic change and wellbeing - challenges ahead

- Chronic and degenerative diseases gain importance in the context of the ageing population
- Health expenditure at 10% of GDP - more than 70% of healthcare spending on chronic diseases

= > Need for innovation and transformation of health care interventions and health systems and services

**EU must catch up with global health innovation leaders and keep its biomedical industry**

# FP7 Health Cooperation programme

## Key figures

**6.1** € billion invested

**1,050** projects

**11,000** teams

**3,500** organisations

**130** countries

## First outcomes

(on 370 closed projects)

**230** patent applications

**34** spin-offs

**12,500** publications

**8** average publication IF

# 1004 collaborative projects in health research from 2007-13



NanoMal project - malaria, now, Dengue, Chagas or yellow fever, soon!



## **Horizon 2020 'Health, demographic change and wellbeing'**


**Translate science into benefit  
for citizens**

**Improve health outcomes**


**Support a competitive health  
and care sector**

**Promote healthy and active  
ageing**

# Funding for Health/Biotech in H2020



# New approaches and new means for supporting health research and innovation at EU-level



# Collaborative research



**€1.2 billion for the Work Programme 2014/15**


**Challenge-driven**

**Broad topics, bottom-up approach**

**Spotlight on 'personalising health and care' and 'coordination'**

**Strong focus on end users**

# Innovative Medicines Initiative 2



IMI 2:  
~€3.2 billion  
EC: €1.6b;  
EFPIA (€1.4b)- other (€0.2b)

- Coverage of the entire medical research and innovation value chain
- Strategic Research Agenda based on the WHO Priority Medicine Report renewed in July 2013
- Involve life science industries other than pharmaceuticals (diagnostics, imaging, animal health, ICT, ...)
- **World class research and innovation leading to breakthrough vaccines, medicines and treatments**

# Innovative Medicines Initiative 2

## First Call:

**Type 1 diabetes**

**Retinal diseases**

**Deadline for submission: 12 November 2014**

## Second Call: Ebola

**Deadline for submission: 1 December 2014**

## Third/Forth Call:

### Research and Innovation Actions:

- Assessing Risk and Progression of Pre-diabetes and Type 2 Diabetes to Enable Disease Modification (SGG Diabetes)
- Towards a Quantitative Biological Approach for Neuropsychiatry
- Programme on Remote Assessment of Disease and Relapse (RADAR) (SGG Data & Knowledge Management)
- Enabling Patient-Centered Medicine Development through a Patient-Inspired Knowledge Hub (PIKH) (SGG Data & Knowledge Management)
- Consistency of Approach for Vaccines Quality Testing (SGG Infections Control)
- Pertussis Vaccines (SGG Infections Control)

### Coordination and Support Action:


- Medicines Adaptive Pathways to Patients (ex-SGG MAPPs)

**Deadline for submission: March-April 2015**

HORIZON 2020



# EDCTP 2



**EDCTP 2:**  
**~€1.37 Billion**  
EC: €683m – Member States: €683m

- **Almost €700 million EU co-funding, match the same member states contribution**

**Broader scope:**  
**including HIV, TB, malaria, neglected infectious diseases, all clinical phases, diagnostics and delivery optimisation**

**Longer duration:**  
**10 years**

**EDCTP Association established in April 2014\***

**EDCTP2 launch : 2 December 2014, Cape Town**

**HORIZON 2020**

\* Cameroon, Congo (Brazzaville), The Gambia, Ghana, Mozambique, Niger, Senegal, South Africa, Tanzania, Uganda, Zambia  
Austria, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Switzerland (as so-called 'aspirant member'), the United Kingdom





## Active and Assisted Living 2

**AAL 2:**  
**~€700 million**  
EC: €175m – Member States: €175m  
Industry: €350m



**More EU funding of up to €175 million**

**Participating countries pay €175 million**

**Additional contribution of €350 million from industrial partners**

**Market-oriented ICT research in assisted living technologies and services**

**New instruments e.g. prizes and innovation grants**



# General opening

- Horizon 2020 is open to participation from across the world
- Automatic funding:
  - Member States (including overseas departments and overseas territories)
  - Associated Countries
  - Exhaustive list of countries in annex to work programme (BRIC + Mexico no longer in this list!)
- Participants from other countries funded in exceptional cases:
  - when provision is made in the call text
  - bilateral agreement (e.g. health challenge – NIH)
  - when the Commission deems it essential (case by case assessment)
- **Program level cooperation**




HORIZON 2020



HORIZON 2020

an  
Commission

# SME instrument




# Financial instruments

H2020:  
~€2.8 billion

- **InnovFin Large Projects**
  - Loans from €7.5 m to €300 m; delivered directly by EIB
- **InnovFin MidCap Growth Finance**
  - Loans from €7.5 m to €25 m; delivered directly by EIB
- **InnovFin MidCap Guarantee**
  - Guarantees to financial intermediaries (banks, etc.)
  - Loans from €7.5 m to €25 m; implemented by EIB
- **InnovFin SME Guarantee**
  - Guarantees / counter-guarantees to financial intermediaries
  - Loans from €25,000 to €7.5 m; implemented by EIF
- **InnovFin Advisory**
  - Improve 'bankability' of large projects

# Financial instruments: how it works



# Innovation inducement prizes



**'This technology could save lives – exactly the type of innovation an EU inducement prize should support'**

Máire Geoghegan-Quinn, European Commissioner for Research and Innovation

# Ability to respond quickly to emerging challenges: Ebola

- **On-going Ebola Research – FP7 projects:** using flexibility within on-going projects
- **' Ebola Exceptional Procedure' – Horizon 2020:** first time ever use of provisions in Financial Regulation (art 128) and its Rules of application (art 190) to award grants without a call for proposals *"in exceptional and duly substantiated emergencies"*

**EbolaVac: coordinator GlaxoSmithKline (BE)** Phase II clinical trials in Europa and Africa on most advanced vaccine candidate ChAd3-EBOV (trials to start in November in WHO and humanitarian aid org. and in January in Mali, Cameroon, Ghana and Nigeria) – EU funding €15.2m

**REACTION: coordinator INSERM (FR)** Safety and efficacy of favipiravir (licensed for influenza) in animal model and in phase I and II studies (trials to start in December) – EU funding €2.6m

**Ebola\_Tx: Prins Leopold Instituut for Tropische Geneeskunde (BE)** Safety, efficacy and feasibility of plasma from survivors of Ebola infection (trials to start in December in Guinea) – EU funding €2.9m

**EVIDENT: Bernhard-Nocht Institut für Tropenmedizin (DE)** Host-pathogen interaction, transmissibility of the virus in various body fluids and understanding the mutations of the virus – EU funding €1.8m

**IF-EBOLa: Institut de Recherche pour le Développement (F)** Safety and efficacy of passive immunotherapy by deploying horse serum containing antibodies against Ebola (testing to start mid-2015 in Guinea and Sierra Leone) – EU funding €2.9m

# First call in Ebola+ programme on Ebola and other filoviral diseases of the Innovative Medicines Initiative (IMI2)

- ❑ the EU Commission and the EU pharmaceutical industry has launched a **€280 million call for proposals** to boost research on Ebola
- ❑ **€140 million from Horizon 2020** and €140 million from the pharmaceutical companies (members of the EU Federation of Pharmaceutical Industries and Associations - EFPIA).
- ❑ The call for proposals will use **a new fast-track procedure** to get successful projects up and running early next year.
- ❑ Topics in the call address **vaccine development** Phase I, II, and III; Manufacturing capability; Stability of vaccines during transport and storage; Deployment and compliance of vaccination regimens as well as Rapid diagnostic tests
- ❑ More topics to come next year

## **EDCTP2**

- Included Ebola and other emerging pathogens of risk to Africa in its work programme → possibility to fund clinical trials on drugs, vaccines, diagnostics in upcoming calls
- Urge Participating States to increase 2014/2015 budget and coordinate relevant research activities

## **International collaboration**

- WHO
- Bill and Melinda Gates Foundation
- Wellcome Trust
- US, Canada, Australia, South Africa, Brazil , France, Spain, Thailand, Korea via GloPID-R
- Initiated working group under EU Health research programme Committee

# Information about all EU funding opportunities on the Participant Portal – your one-stop shop

(A-Z) Sitemap About this site Contact Legal Notice Search English

RESEARCH & INNOVATION  
Participant Portal

European Commission > Research & Innovation > Participant Portal > Home

HOME FUNDING OPPORTUNITIES HOW TO PARTICIPATE EXPERTS SUPPORT

LOGIN REGISTER

## Horizon 2020 Funding

Starting from 1/1/2014

On this site you can find and secure **funding** for research & innovation projects under the following EU programmes:

- 2014-2020 Horizon 2020 - research and innovation framework programme
- 2007-2013 7th research framework programme (FP7) and Competitiveness & Innovation Programme (CIP)

**Non-registered users**


- search for funding
- read the H2020 Online Manual & download the legal documents
- check if an organisation is already registered
- contact our support services or check our FAQs

**Registered users**

- submit your proposal
- sign the grant
- manage your project throughout its lifecycle

W E N A E=MC²

http://ec.europa.eu/research/participants/portal





# Thank you !

[ruxandra.draghia-akli@ec.europa.eu](mailto:ruxandra.draghia-akli@ec.europa.eu)

HORIZON 2020